CD274 and cancer: Although tumor cells were initially regarded as the predominant source of PD-L1 for immune suppression, clinical trials showed that cancer patients with PD-L1-negative tumors can benefit from PD-1/PD-L1 blockade therapy, implying the involvement of PD-L1 on host cells in this effect [46].